Publications in collaboration with researchers from Sarah Cannon Research Institute (3)

2021

  1. Tolerability and antitumor activity of cemiplimab, a human monoclonal anti–PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort

    Lung Cancer, Vol. 155, pp. 151-155

2020

  1. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer

    Lung Cancer, Vol. 142, pp. 63-69

2019

  1. Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC

    Journal of Thoracic Oncology, Vol. 14, Núm. 10, pp. 1828-1838